Document Detail

Hemostasis activation in thrombophilic subjects with or without a history of venous thrombosis.
MedLine Citation:
PMID:  17895509     Owner:  NLM     Status:  MEDLINE    
Thrombophilia is considered to increase the risk of venous thrombosis (VT) due to hemostasis activation. To determine the level of hemostasis activation in thrombophilic subjects with or without a history of VT, hemostasis activation markers prothrombin fragment 1 and 2 (F1+2), thrombin-antithrombin complex (TAT), and cross-linked fibrin degradation products (D-dimer) were measured in 94 subjects with (patients) and 101 subjects without a history of VT (controls). A total of 34.8% of patients and 14.8% of controls (P= .002) had at least 1 thrombophilic defect (protein C deficiency, activated protein C [APC] resistance, presence of lupus anticoagulants, or prothrombin G20210A polymorphism). The subjects were divided into 4 subgroups: patients with (TF(+) patients) and without (TF(-) patients) thrombophilia, and controls with (TF(+) controls) and without (TF(-) controls) thrombophilia. Hemostasis activation was comparable between all patients and controls (TAT: 2.1 vs 2.6 microg/L; F1+2: 1.0 vs 0.9 nmol/L; D-dimer: 36 vs 37 microg/L, respectively) and between TF(+) and TF(- ) patients. However, TF(+) controls had a significantly higher prevalence of increased hemostasis activation markers compared with TF(-) controls (TAT>4.4 microg/L, 38.4 vs 7.3%; F1+2>1.1 nmol/L, 53.8 vs 22.0%; D-dimer >78 microg/L, 30.7 vs 8.8% of subjects, respectively; all P< .05). After stratification for thrombophilic defects, hemostasis activation was associated with APC resistance in controls and with protein C deficiency in patients. To conclude, thrombophilia was associated with hemostasis activation in controls. We assumed that, in patients, the differences in hemostasis activation between subjects with or without thrombophilia were blurred due to undetermined and unidentified thrombophilic defects.
Tjasa Vizintin Cuderman; Mojca Bozic; Polona Peternel; Mojca Stegnar
Related Documents :
2506659 - Clotting activation and impairment of fibrinolysis in malignancy.
2453419 - Study on a new chromogenic substrate for the prothrombin time determination.
18345709 - Recombinant factor viia (eptacog alfa): a review of its use in congenital hemophilia wi...
1977979 - Coagulation factor abnormalities as possible thrombotic risk factors after fontan opera...
21439749 - Comparison between a clinical activity index (harvey-bradshaw-index), laboratory inflam...
21831329 - Influence of degree of specific allergic sensitivity on severity of rhinitis and asthma...
18199519 - Tenofovir monotherapy is effective in hepatitis b patients with antiviral treatment fai...
16027399 - Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population.
8692469 - Scintigraphic diagnosis of subclinical cushing's syndrome in patients with adrenal inci...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-09-25
Journal Detail:
Title:  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis     Volume:  14     ISSN:  1076-0296     ISO Abbreviation:  Clin. Appl. Thromb. Hemost.     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2008-01-09     Completed Date:  2008-02-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9508125     Medline TA:  Clin Appl Thromb Hemost     Country:  United States    
Other Details:
Languages:  eng     Pagination:  55-62     Citation Subset:  IM    
Department of Angiology, University Medical Centre, Ljubljana, Slovenia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Biological Markers / blood
Case-Control Studies
Middle Aged
Protein C Deficiency
Thrombophilia / blood*
Venous Thrombosis / blood*
Reg. No./Substance:
0/Biological Markers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The activated seven lupus anticoagulant assay detects clinically significant antibodies.
Next Document:  Multifactorial thrombophilia in a pregnancy: a case report.